Targeting Enterotoxins: Advancing Vaccine Development for Enterotoxigenic Escherichia coli ETEC
Toxins · 06.02.2025 · 17 (2) · 71
DOI: 10.3390/toxins17020071 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Toxins, online erschienen am 06.02.2025. Verfasst von Josune Salvador-Erro und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Parasitology, Navarra Medical Research Institute (IdiSNA), University of Navarra, 31008 Pamplona, Spain. Hauptthemen laut MEDLINE: Enterotoxigenic Escherichia coli, Escherichia coli Infections, Enterotoxins, Escherichia coli Vaccines. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 160 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Y.P. has received funding from the "Gobierno de Navarra, Spain-Next Generation EU" program., “Gobierno de Navarra, Spain-Next Generation EU” Program.
Abstract (Originalsprache)
Enterotoxigenic Escherichia coli (ETEC) is a major cause of diarrheal disease worldwide, particularly in children in low- and middle-income countries. Its ability to rapidly colonize the intestinal tract through diverse colonization factors and toxins underpins its significant public health impact. Despite extensive research and several vaccine candidates reaching clinical trials, no licensed vaccine exists for ETEC. This review explores the temporal and spatial coordination of ETEC virulence factors, focusing on the interplay between adherence mechanisms and toxin production as critical targets for therapeutic intervention. Advancements in molecular biology and host–pathogen interaction studies have uncovered species-specific variations and cross-reactivity between human and animal strains. In particular, the heat-labile (LT) and heat-stable (ST) toxins have provided crucial insights into molecular mechanisms and intestinal disruption. Additional exotoxins, such as EAST-1 and hemolysins, further highlight the multifactorial nature of ETEC pathogenicity. Innovative vaccine strategies, including multiepitope fusion antigens (MEFAs), mRNA-based approaches, and glycoconjugates, aim to enhance broad-spectrum immunity. Novel delivery methods, like intradermal immunization, show promise in eliciting robust immune responses. Successful vaccination against ETEC will offer an effective and affordable solution with the potential to greatly reduce mortality and prevent stunting, representing a highly impactful and cost-efficient solution to a critical global health challenge.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Parasitology, Navarra Medical Research Institute (IdiSNA), University of Navarra, 31008 Pamplona, Spain.
ORCID-Profile: Josune Salvador-Erro, Yadira Pastor, Carlos Gamazo
Förderung
- Y.P. has received funding from the "Gobierno de Navarra, Spain-Next Generation EU" program.
- “Gobierno de Navarra, Spain-Next Generation EU” Program
Zitieren
APA
Salvador-Erro, J., Pastor, Y., & Gamazo, C. (2025). Targeting Enterotoxins: Advancing Vaccine Development for Enterotoxigenic Escherichia coli ETEC. Toxins, 17(2), 71. https://doi.org/10.3390/toxins17020071
Vancouver
Salvador-Erro J, Pastor Y, Gamazo C. Targeting Enterotoxins: Advancing Vaccine Development for Enterotoxigenic Escherichia coli ETEC. Toxins. 2025;17(2):71. doi:10.3390/toxins17020071
BibTeX
@article{SalvadorErro2025,
author = {Salvador-Erro, Josune and Pastor, Yadira and Gamazo, Carlos},
title = {Targeting Enterotoxins: Advancing Vaccine Development for Enterotoxigenic Escherichia coli ETEC},
journal = {Toxins},
year = {2025},
volume = {17},
number = {2},
pages = {71},
doi = {10.3390/toxins17020071}
}
EUVIMED